Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PIPE-307 · 3 trials · 2 indications
Number of participants with TEAEs
Number of participants with TEAEs
| Arm | Type | Description |
|---|---|---|
| PIPE-307 Dose A | EXPERIMENTAL | - |
| PIPE-307 Dose B | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| PIPE-307 | EXPERIMENTAL | Subjects will receive an oral dose of PIPE-307 and 3 intravenous injections of \[11C\] PIPE- 307. |
| Name | Type | Description |
|---|---|---|
| PIPE-307 Dose A | DRUG | Subjects will receive daily oral doses of PIPE-307 |
| PIPE-307 Dose B | DRUG | Subjects will receive daily oral doses of PIPE-307 |
| Placebo | DRUG | Subjects will receive daily oral matching dose of Placebo |
| PIPE-307 | DRUG | Each dose cohort will receive a single oral dose of PIPE-307. Doses to be tested in subsequent cohorts will be determined by the analysis of the exposure from PK data and the PET scans with \[11C\] PIPE-307. Subjects will receive an intravenous dose of the radioligand \[11C\] PIPE-307 prior to PET imaging. |
| Placebo oral tablet | DRUG | Single and multiple ascending oral doses of matching Placebo tablets |
Inclusion Criteria: * Subject is fluent in English. * Male or female 18 to 50 years of age, inclusive, at the first Screening visit. * A diagnosis of relapsing-remitting multiple sclerosis (RRMS) according to the 2017 Revised McDonald Criteria. * Expanded Disability Status Scale (EDSS) and retinal ...
PIPE-307 is an investigational small molecule being developed for the treatment of multiple sclerosis, including relapsing remitting multiple sclerosis. It is designed as a selective muscarinic M1 receptor agonist with the goal of promoting remyelination in patients with demyelinating diseases such as MS.
PIPE-307 targets the muscarinic M1 receptor, a G protein-coupled receptor. By selectively activating this receptor, PIPE-307 is intended to stimulate oligodendrocyte precursor cells to differentiate and remyelinate damaged axons, offering a potential approach to restoring neurological function in multiple sclerosis.
PIPE-307 is being developed by Contineum Therapeutics, Inc., a clinical-stage biopharmaceutical company. Contineum Therapeutics trades on the Nasdaq under the ticker symbol CTNM. The company focuses on discovering and developing novel therapies for neuroscience and immunology indications.
PIPE-307 is in Phase 1 clinical development, with completed Phase 1 trials in healthy volunteers. A Phase 2 trial in relapsing remitting multiple sclerosis has also been completed. The drug remains investigational and has not been approved by the FDA for any indication.
PIPE-307 has been evaluated in three completed clinical trials. These include a Phase 2 study in relapsing remitting multiple sclerosis (NCT06083753), a Phase 1 PET study in healthy volunteers (NCT04941781), and a Phase 1 single and multiple ascending dose study with food effect assessment (NCT04725175).
Yes, PIPE-307 Dose A is an alternative name for PIPE-307. Both refer to the same investigational small molecule developed by Contineum Therapeutics for multiple sclerosis. The dose designation may be used in certain study contexts, but the underlying drug candidate is identical.